For individuals considering weight loss medication, understanding these differences is critical
Diabetes 65 (6), 17141723
Studies of semaglutide have not identified PPIs as problematic co-medications, and omeprazole's metabolism is not affected by GLP-1 receptor agonists
The prospect of combining health benefits, including improved metabolic outcomes and reduced cardiovascular risks, adds another layer of optimism
With this information, healthcare providers can craft weight loss plans that address cholesterol management
As with any wellness change, we advocate for a "foundations first" approach: focusing on sleep, hydration, and safety before thoughtfully adding targeted support